TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Daigeler, Adrien ^a   Brenzel, Christina ^b   Bulut, Daniel ^b   Geisler, Anne ^b   Hilgert, Christoph ^b   Lehnhardt, Marcus ^a   Steinau, Hans U ^a   Flier, Annegret ^a   Steinstraesser, Lars ^a   Klein Hitpass, Ludger ^c   Mittelkötter, Ulrich ^b   Uhl, Waldemar ^b   Chromik, Ansgar M ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45A; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 14; MYC PROTEIN; NUCLEAR FACTOR; PROTEIN HSPA1A; PROTEIN HSPA1B; PROTEIN NFKBIA; PROTEIN SERINE THREONINE KINASE; PROTEIN TNFAIP3; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RHO FACTOR; RHO GUANOSINE DIPHOSPHATE DISSOCIATION INHIBITOR A; SERUM AND GLUCOCORTICOID REGULATED KINASE; TAUROLIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAURINE; THIADIAZINE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSARCOMA; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL GROWTH; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROSARCOMA; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; NF-KAPPA B; TAURINE; THIADIAZINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 60549100517     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-82     Document Type: Article

References (78)

1. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. S Singer JM Corson GD Demetri EA Healey K Marcus TJ Eberlein, Ann Surg 1995 221 2 185 195 7857146
2. The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of Cancer. E Donato Di Paola OS Nielsen, Eur J Cancer 2002 38 Suppl 4 S138 S141 11858980
3. The potential of TRAIL for cancer chemotherapy. M Nagane HJ Huang WK Cavenee, Apoptosis 2001 6 3 191 197 11388668
4. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. DW Leaman M Chawla-Sarkar K Vyas M Reheman K Tamai S Toji EC Borden, J Biol Chem 2002 277 32 28504 28511 12029096
5. Lethal effect of the anti-Fas antibody in mice. J Ogasawara R Watanabe-Fukunaga M Adachi A Matsuzawa T Kasugai Y Kitamura N Itoh T Suda S Nagata, Nature 1993 364 6440 806 809 7689176
6. Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. WS Tsai WS Yeow A Chua RM Reddy DM Nguyen DS Schrump DM Nguyen, Mol Cancer Ther 2006 5 12 2977 2990 17172403
7. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma. K Kondo S Yamasaki N Inoue T Sugie N Teratani T Kan Y Shimada, Surg Today 2006 36 11 966 974 17072716
8. Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. H Dalen J Neuzil, Br J Cancer 2003 88 1 153 158 12556975
9. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. T Weber M Lu L Andera H Lahm N Gellert MW Fariss V Korinek W Sattler DS Ucker A Terman, Clin Cancer Res 2002 8 3 863 869 11895920
10. The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. C Braumann W Henke CA Jacobi W Dubiel, Int J Cancer 2004 112 2 225 230 15352034
11. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. P Calabresi FA Goulette JW Darnowski, Cancer Res 2001 61 18 6816 6821 11559556
12. Taurolidine inhibits tumor cell growth in vitro and in vivo. M McCourt JH Wang S Sookhai HP Redmond, Ann Surg Oncol 2000 7 9 685 691 11034247
13. Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. C Braumann G Winkler P Rogalla C Menenakos CA Jacobi, World J Surg Oncol 2006 4 34 16796759
14. Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients. R Stendel L Scheurer K Schlatterer U Stalder RW Pfirrmann I Fiss H Mohler L Bigler, Clin Pharmacokinet 2007 46 6 513 524 17518510
15. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. R Stendel L Scheurer G Stoltenburg-Didinger M Brock H Mohler, Anticancer Res 2003 23 3B 2309 2314 12894508
16. Taurolidine inhibits tumour necrosis factor (TNF) toxicity - new evidence of TNF and endotoxin synergy. JR Monson PS Ramsey JH Donohue, Eur J Surg Oncol 1993 19 3 226 231 8314379
17. The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Z Han I Ribbizi P Pantazis J Wyche J Darnowski P Calabresi, Anticancer Res 2002 22 4 1959 1964 12174870
18. Taurolidine: preclinical evaluation of a novel, highly selective, agent for bone marrow purging. I Ribizzi JW Darnowski FA Goulette MS Akhtar D Chatterjee P Calabresi, Bone Marrow Transplant 2002 29 4 313 319 11896428
19. Taurolidine - a new drug with anti-tumor and anti-angiogenic effects. CA Jacobi C Menenakos C Braumann, Anticancer Drugs 2005 16 9 917 921 16162968
20. Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. AM Chromik A Daigeler C Hilgert D Bulut A Geisler V Liu JM Otte W Uhl U Mittelkotter, J Invest Surg 2007 20 6 339 348 18097875
21. Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. A Daigeler AM Chromik A Geisler D Bulut C Hilgert A Krieg L Klein-Hitpass M Lehnhardt W Uhl U Mittelkotter, Int J Oncol 2008 32 6 1205 1220 18497982
22. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. S Tomek W Koestler P Horak T Grunt T Brodowicz I Pribill J Halaschek G Haller C Wiltschke CC Zielinski, Eur J Cancer 2003 39 9 1318 1329 12763223
23. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. PM de Angelis B Fjell KL Kravik T Haug SH Tunheim W Reichelt M Beigi OP Clausen E Galteland T Stokke, Int J Oncol 2004 24 5 1279 1288 15067352
24. LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane. T Ota M Maeda S Suto M Tatsuka, Mol Carcinog 2004 39 4 206 220 15057873
25. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. H Ying SL Biroc WW Li B Alicke JA Xuan R Pagila Y Ohashi T Okada Y Kamata H Dinter, Mol Cancer Ther 2006 5 9 2158 2164 16985048
26. A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. JT Cooper DM Stroka C Brostjan A Palmetshofer FH Bach C Ferran, J Biol Chem 1996 271 30 18068 18073 8663499
27. Inhibition of tumor necrosis factor-induced necrotic cell death by the zinc finger protein A20. K Heyninck G Denecker D De Valck W Fiers R Beyaert, Anticancer Res 1999 19 4B 2863 2868 10652565
28. [Regulation of NF-kappaB/P65 by MDM2 in acute lymphoblastic leukemia in childhood]. Q Hu MX Zhou SY Liu LQ Zhang AQ Liu YJ Guo Y Song, Zhonghua Er Ke Za Zhi 2003 41 12 921 924 14723816
29. Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases. HJ Park HJ Chung HY Min EJ Park JY Hong WB Kim SH Kim SK Lee, Biochem Pharmacol 2005 71 1-2 21 31 16271263
30. Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-kappaB activation. JM Park A Kim JH Oh AS Chung, Carcinogenesis 2007 28 4 837 847 17071627
31. Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. DK Walters R Muff B Langsam P Gruber W Born B Fuchs, Invest New Drugs 2007 25 4 305 312 17458504
32. Anti-inflammatory effects of taurine derivatives (taurine chloramine, taurine bromamine, and taurolidine) are mediated by different mechanisms. J Marcinkiewicz M Kurnyta R Biedron M Bobek E Kontny W Maslinski, Adv Exp Med Biol 2006 583 481 492 17153635
33. Influence of intraperitoneal application of taurolidine/heparin on expression of adhesion molecules and colon cancer in rats undergoing laparoscopy. E Bobrich C Braumann I Opitz C Menenakos G Kristiansen CA Jacobi, J Surg Res 2007 137 1 75 82 17109891
34. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. N Nakatsu Y Yoshida K Yamazaki T Nakamura S Dan Y Fukui T Yamori, Mol Cancer Ther 2005 4 3 399 412 15767549
35. Drug evaluation: STA-4783 - enhancing taxane efficacy by induction of Hsp70. M Gehrmann, Curr Opin Investig Drugs 2006 7 6 574 580 16784029
36. Taurine: new implications for an old amino acid. GB Schuller-Levis E Park, FEMS Microbiol Lett 2003 226 2 195 202 14553911
37. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. QS Zhu W Ren B Korchin G Lahat A Dicker Y Lu G Mills RE Pollock D Lev, Cancer Res 2008 68 8 2895 2903 18413758
38. Distinct signaling pathways in TRAIL-versus tumor necrosis factor-induced apoptosis. Z Jin WS El-Deiry, Mol Cell Biol 2006 26 21 8136 8148 16940186
39. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines. T Mikami T Koyama T Koyama A Imakiire K Yamamoto M Furuhata H Toyota J Mizuguchi, Anticancer Res 2006 26 2A 1153 1160 16619517
40. Profiling the molecular difference between Patched- and p53-dependent rhabdomyosarcoma. R Kappler R Bauer J Calzada-Wack M Rosemann B Hemmerlein H Hahn, Oncogene 2004 23 54 8785 8795 15480423
41. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. S Papa F Zazzeroni C Bubici S Jayawardena K Alvarez S Matsuda DU Nguyen CG Pham AH Nelsbach T Melis, Nat Cell Biol 2004 6 2 146 153 14743220
42. Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase. L Zhang R Cui X Cheng J Du, Cancer Res 2005 65 2 457 464 15695387
43. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines. T Mikami T Koyama A Imakiire K Yamamoto M Furuhata H Toyota J Mizuguchi, Anticancer Res 2006 26 2A 1153 1160 16619517
44. Carboxylated chitooligosaccharides (CCOS) inhibit MMP-9 expression in human fibrosarcoma cells via down-regulation of AP-1. N Rajapakse MM Kim E Mendis R Huang SK Kim, Biochim Biophys Acta 2006 1760 12 1780 1788 17020790
45. 1-furan-2-yl-3-pyridin-2-yl-propenone inhibits the invasion and migration of HT1080 human fibrosarcoma cells through the inhibition of proMMP-2 activation and down regulation of MMP-9 and MT1-MMP. BC Park D Thapa YS Lee MK Kwak ES Lee HG Choi CS Yong JA Kim, Eur J Pharmacol 2007 567 3 193 197 17507007
46. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. U Senftleben Y Cao G Xiao FR Greten G Krahn G Bonizzi Y Chen Y Hu A Fong SC Sun, Science 2001 293 5534 1495 1499 11520989
47. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. C Thallinger MF Wolschek H Maierhofer H Skvara H Pehamberger BP Monia B Jansen V Wacheck E Selzer, Clin Cancer Res 2004 10 12 Pt 1 4185 4191 15217956
48. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. S Shukla S Gupta, Clin Cancer Res 2004 10 9 3169 3178 15131058
49. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. CY Wang MW Mayo AS Baldwin Jr, Science 1996 274 5288 784 787 8864119
50. NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B. D Javelaud F Besancon, Oncogene 2001 20 32 4365 4372 11466617
51. The transcription factor nuclear factor-kappa B and cancer. RO Escarcega S Fuentes-Alexandro M Garcia-Carrasco A Gatica A Zamora, Clin Oncol (R Coll Radiol) 2007 19 2 154 161 17355113
52. Transcriptional regulation via the NF-kappaB signaling module. A Hoffmann G Natoli G Ghosh, Oncogene 2006 25 51 6706 6716 17072323
53. NFkappaB pathway: a good signaling paradigm and therapeutic target. V Tergaonkar, Int J Biochem Cell Biol 2006 38 10 1647 1653 16766221
54. Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors. KJ Campbell JM O'Shea ND Perkins, BMC Cancer 2006 6 101 16630341
55. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. M Lauricella S Emanuele A D'Anneo G Calvaruso B Vassallo D Carlisi P Portanova R Vento G Tesoriere, Apoptosis 2006 11 4 607 625 16528474
56. Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. M Lehnhardt L Klein-Hitpass C Kuhnen HH Homann A Daigeler HU Steinau S Roehrs L Schnoor L Steinstraesser O Mueller, BMC Cancer 2005 5 74 16001973
57. Role of GADD34 in modulation of cisplatin cytotoxicity. ML Fishel CA Rabik WK Bleibel X Li RC Moschel ME Dolan, Biochem Pharmacol 2006 71 3 239 247 16325149
58. Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. MC Hollander Q Zhan I Bae AJ Fornace Jr, J Biol Chem 1997 272 21 13731 13737 9153226
59. Differential cooperation of oncogenes with p53 and Bax to induce apoptosis in rhabdomyosarcoma. AC Taylor K Schuster PP McKenzie LC Harris, Mol Cancer 2006 5 53 17081294
60. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. T Nakano M Tani Y Ishibashi K Kimura YB Park N Imaizumi H Tsuda K Aoyagi H Sasaki S Ohwada, Clin Exp Metastasis 2003 20 7 665 674 14669798
61. Gas6/Axl signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to protect oligodendrocytes from tumor necrosis factor alpha-induced apoptosis. SL Shankar K O'Guin M Kim B Varnum G Lemke CF Brosnan B Shafit-Zagardo, J Neurosci 2006 26 21 5638 5648 16723520
62. Gas6 anti-apoptotic signaling requires NF-kappa B activation. F Demarchi R Verardo B Varnum C Brancolini C Schneider, J Biol Chem 2001 276 34 31738 31744 11425860
63. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. D Sarkar ZZ Su IV Lebedeva M Sauane RV Gopalkrishnan K Valerie P Dent PB Fisher, Proc Natl Acad Sci USA 2002 99 15 10054 10059 12114539
64. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. M Kilic H Kasperczyk S Fulda KM Debatin, Oncogene 2007 26 14 2027 2038 17043658
65. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. T Nomura M Yamasaki Y Nomura H Mimata, Oncol Rep 2005 14 4 993 997 16142363
66. (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. E Varfolomeev D Vucic, Cell Cycle 2008 7 11 18469528
67. Interaction of calreticulin with CD40 ligand, TRAIL and Fas ligand. K Duus RT Pagh U Holmskov P Hojrup S Skov G Houen, Scand J Immunol 2007 66 5 501 507 17953526
68. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. N Chaput S De Botton M Obeid L Apetoh F Ghiringhelli T Panaretakis C Flament L Zitvogel G Kroemer, J Mol Med 2007 85 10 1069 1076 17891368
69. Dual-specificity phosphatase 1: a critical regulator of innate immune responses. SM Abraham AR Clark, Biochem Soc Trans 2006 34 Pt 6 1018 1023 17073741
70. A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. A Vogt PR McDonald A Tamewitz RP Sikorski P Wipf JJ Skoko 3rd JS Lazo, Mol Cancer Ther 2008 7 2 330 340 18245669
71. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. J Sanceau J Hiscott O Delattre J Wietzerbin, Oncogene 2000 19 30 3372 3383 10918594
72. Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B. J Sanceau DD Boyd M Seiki B Bauvois, J Biol Chem 2002 277 38 35766 35775 12105194
73. Role of Bag-1 in the survival and proliferation of the cytokine-dependent lymphocyte lines, Ba/F3 and Nb2. CV Clevenger K Thickman W Ngo WP Chang S Takayama JC Reed, Mol Endocrinol 1997 11 5 608 618 9139804
74. Clk-1 deficiency induces apoptosis associated with mitochondrial dysfunction in mouse embryos. M Takahashi T Shimizu E Moriizumi T Shirasawa, Mech Ageing Dev 2008 129 5 291 298 18343482
75. Met expression and sarcoma tumorigenicity. S Rong M Jeffers JH Resau I Tsarfaty M Oskarsson GF Vande Woude, Cancer Res 1993 53 22 5355 5360 7693339
76. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. R Taulli C Scuoppo F Bersani P Accornero PE Forni S Miretti A Grinza P Allegra M Schmitt-Ney T Crepaldi, Cancer Res 2006 66 9 4742 4749 16651427
77. Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1. C Widmann NL Johnson AM Gardner RJ Smith GL Johnson, Oncogene 1997 15 20 2439 2447 9395240
78. Activation of transcription factors NF-kappaB and AP-1 and their relations with apoptosis associated-proteins in hepatocellular carcinoma. LL Guo S Xiao Y Guo, World J Gastroenterol 2005 11 25 3860 3865 15991283